New eczema drug enters first human safety trials

NCT ID NCT06055361

Recruiting now Symptom relief Sponsor: Brexogen Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 22 times

Summary

This early-stage study tests a new drug called BxC-I17e in 45 adults with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and tolerable when given as a shot under the skin. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and any signs that the drug helps their skin.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arkansas Research Trials
RECRUITING

North Little Rock, Arkansas, 72117, United States

Contact
DermDox Centers for Dermatology
RECRUITING

Camp Hill, Pennsylvania, 17011, United States

Contact
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS